BioLineRx Shows GLIX1 Plus Olaparib Matches Cisplatin Efficacy in Ovarian Cancer Model
BLRX•In a six-arm patient-derived ovarian cancer xenograft model, low-dose GLIX1 plus olaparib matched cisplatin’s tumor reduction and outperformed each monotherapy at optimal doses. Findings of strong synthetic lethality in homologous recombination–proficient tumors support adding an ovarian cancer cohort to BioLineRx’s Phase 1/2a GLIX1 trial.
1. Preclinical Study Design and Results
The study included six arms: cisplatin, GLIX1 monotherapy, olaparib monotherapy, low-dose GLIX1, low-dose GLIX1/olaparib combination, and a control group. The low-dose combination achieved tumor reduction comparable to cisplatin and exceeded efficacy of each agent alone at optimal doses.
2. Mechanistic Insights
GLIX1 induces single-stranded DNA breaks that, when combined with PARP inhibition, overwhelm DNA repair in homologous recombination–proficient ovarian cancer cells. High synergy scores across in vitro and in vivo models confirm a synthetic lethality mechanism capable of sensitizing tumors resistant to PARP inhibitors.
3. Trial Expansion Plans
Based on these encouraging preclinical results, BioLineRx will add an ovarian cancer arm to its ongoing Phase 1/2a GLIX1 trial. The expansion aims to evaluate safety, optimal dosing, and preliminary efficacy in homologous recombination–proficient and platinum-resistant ovarian cancer patients.
